

Based on the detailed PDF report provided for **LUPIN.NS** (dated 2026-01-31), here is the analysis from the perspective of a Positional Equity Trader.

Step 1: Audit the Data

- * **Data Present:**
 - * **Price Structure:** Daily, Weekly, and 15-min candlestick charts with moving averages (EMA 20, 50, 200).
 - * **Trend Indicators:** Supertrend, MACD, and EMA crossover status.
 - * **Volatility:** Bollinger Bands and Volatility Squeeze analysis.
 - * **Momentum/Strength:** RSI (Relative Strength Index) and Comparative Relative Strength (RS) against the Pharma sector.
 - * **Volume:** Distribution day analysis and Volume moving averages.
 - * **Fundamentals:** Snapshot of revenue/net income growth and valuation metrics.
- * **Data Missing:**
 - * **Fibonacci Retracement:** Specific retracement levels from the recent swing low/high are not explicitly drawn.
 - * **Order Book/Market Depth:** Real-time buying/selling pressure is not visible (standard for static reports).
- * **Confidence Level:** **High.** The report provides a comprehensive technical and fundamental picture, allowing for a robust evidenced-based decision.
- * *Note:* The report date is futuristic (2026). I am treating the data as "current" relative to the context of the analysis.

Step 2: Analyze the Setup

- * **Trend & Structure:**
 - * **Primary Trend:** ****Bullish**.** The stock is trading well above the 200 EMA (2027.24) and the Supertrend is positive (Green).
 - * **Intermediate Trend:** **Consolidation/Pullback.** The stock recently pulled back from highs (~2400) and found support at the **50 EMA (2113)**. It is currently sandwiching between the 50 EMA support and the 20 EMA resistance (2148).
- * **Momentum:**
 - * **MACD:** ****Bearish**.** The MACD line is below the signal line (Page 13), indicating the immediate momentum is still negative/corrective. However, the histogram suggests the bearish momentum is fading (bars getting lighter/smaller).
 - * **RSI:** **Neutral (52.70).** It is not overbought, leaving room for upside, but lacks the "thrust" usually seen in breakout setups (>60).
- * **Volume & Supply:**
 - * **Concern:** Page 18 highlights **5 Distribution Days** in late January 2026. This indicates institutional selling or profit-taking during the recent consolidation. This is the primary risk factor preventing an immediate aggressive entry.
- * **Confluence:**
 - * **Support:** Strong confluence of support at the **2100-2115** level (50 EMA + Supertrend Value of 2089).
 - * **Fundamentals:** Net Income is up 57.80% (Quarter-over-Quarter), validating the long-term bullish thesis.

Step 3: Formulate the Recommendation

Verdict: **NO** (Do not enter *immediately* at market price).

Reasoning: While the long-term trend is up, the short-term setup is messy. The stock is currently fighting overhead resistance at the **Middle Bollinger Band (SMA 20)** around 2160 and shows recent signs of distribution (selling volume). Entering exactly at 2152.80 puts you directly into resistance with bearish MACD momentum.

****Strategy:**** You need the price to prove that the "Distribution" phase is over and buyers have regained control of the 20-day average.

Conditional Trading Plan (Watchlist):

- * **Condition to Buy:** Wait for a **Daily Close above INR 2175**.
 - * **Why:** This clears the Middle Bollinger Band (2160) and confirms the reclamation of the 20 EMA, shifting short-term momentum back to bullish.
- * **Entry Price:** **INR 2175 - INR 2185** (On confirmation).
- * **Stop Loss:** **INR 2085** (Hard Stop).
 - * **Why:** This is just below the Supertrend support (2089) and the 50 EMA (2113). If this level breaks, the intermediate trend is violated.
- * **Take Profit:** **INR 2350** (Target 1) / **INR 2400** (Target 2).
 - * **Why:** INR 2350 is the recent resistance zone before the previous peak.
 - * **Risk/Reward:** Risk is ~90 points; Reward is ~175 points (Approx 1:2 ratio).

Summary: Good fundamental stock in a strong primary uptrend, but currently digesting gains. Wait for the trigger (2175+) to avoid "catching a falling knife" or getting stuck in sideways chop.

News & Analyst Targets

Based on the latest available information as of **January 31, 2026**, here is the research update on Lupin Limited (LUPIN).

1) Latest News for LUPIN (Week of Jan 26 - Jan 31, 2026)

- * **Rating Adjustment:** On January 28, 2026, **MarketsMOJO** downgraded Lupin's investment rating from "Strong Buy" to **"Buy"**. The firm cited mixed technical signals as the primary reason, noting that while fundamentals (quality, valuation, financial trend) remain robust, the technical grade has shifted from bullish to "mildly bullish."
- * **Upcoming Q3 Earnings:** Lupin has scheduled a Board of Directors meeting for **February 12, 2026**, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26).
- * **ESOP Allotment:** On January 27, 2026, the company announced the allotment of **169,140 equity shares** to employees under its stock option plans.
- * **ESG Recognition:** Earlier in the week (Jan 23), Lupin received the highest **ESG rating** from the CDP (formerly Carbon Disclosure Project) for its performance in Climate Change and Water Security, underscoring its leadership in sustainability.
- * **Semaglutide Deal:** On January 21, 2026, Lupin signed a license and supply agreement with **Galenicum** to commercialize Semaglutide (a GLP-1 receptor agonist used for diabetes and weight loss) in 23 countries, expanding its footprint in the growing metabolic market.

2) Brokerage Upgrades & Downgrades

- * **MarketsMOJO:** **Downgrade** to **BUY** (from Strong Buy) on Jan 28, 2026.
- * **Citi:** Maintains **BUY** rating (Recent notes cite strong US growth and product pipeline).
- * **Consensus View:** The broader analyst community retains an **"Outperform"** or **"Buy"** sentiment on the stock, with recent breakouts in share price signaling potential bullish momentum despite the minor technical downgrade by MarketsMOJO.

3) Other News Impacting LUPIN

- * **US FDA Observations (Goa Facility):** In late 2025 (November), the US FDA conducted an inspection of Lupin's Goa manufacturing facility which concluded with a **Form-483** citing seven observations. The company is currently in the process of addressing these findings. This remains a key monitorable for investors.
- * **Acquisition Timeline Update:** Lupin has updated the completion timeline for its **?190 million acquisition of VISUfarma B.V.** (Netherlands) to **February 28, 2026**. This move is set to strengthen its ophthalmology presence in Europe.

* **Technical Breakout:** Market experts have noted that Lupin recently broke out of a 7-month consolidation phase, suggesting a potential "bull comeback" with short-term trading targets around INR 2,290.

4) Latest Analyst Targets & Ratings

As of January 31, 2026

Brokerage / Source	Rating	Action	Target Price (INR)	Upside/Downside Potential	Notes
---	---	---	---	---	
Consensus Mean	**Outperform**	**2,306**	**~7.1%**	Average of 19 reports	
Trendlyne Consensus	Buy	**2,347**	**~9.0%**	Based on analyst aggregate	
Technical Analysts	Buy (Short-Term)	**2,290**	**~6.4%**	Momentum-based target	
Nomura / Instinet	Buy	**2,350**	**~9.2%**	Maintained Buy, adjusted PT	
Citi	Buy	**2,260**	**~5.0%**	Upgraded from Sell (Prev Cycle)	
UBS	Sell	**2,050**	**~-4.7%**	Maintained cautious stance	
High Estimate	--	**2,600**	**~20.8%**	Street High Target	
Low Estimate	--	**1,903**	**~-11.6%**	Street Low Target	

Note: Stock price reference taken at ~INR 2,152 (Jan 30, 2026 close).


Stock Detailed Analysis Report

LUPIN.NS

Current Price: ₹2152.80

Generated: 2026-01-31 11:36

LUPIN.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

LUPIN.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.7/100
:	

== RS RATIOS ==:

1M RS:	1.061 [Leader]
3M RS:	1.134 [Leader]
6M RS:	1.132 [Leader]
1Y RS:	1.023 [Leader]
:	




== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✓ Performance Improving:	3M (+10.1%) > 6M (+9.8%)


Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



LUPIN.NS - EMA Crossover Summary

EMA 20:	2148.02
EMA 50:	2113.17
EMA 200:	2027.24
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-13 00:00:00+05:30
Golden Cross Price:	2052.90

LUPIN.NS EMA Crossover Analysis



LUPIN.NS - Bollinger Bands Summary

Current Price:	2152.80
Upper Band:	2226.40
Middle Band (SMA 20):	2160.73
Lower Band:	2095.06
%B:	0.4396
Band Width:	0.0608
Status:	Lower Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-11-17 00:00:00+05:30

LUPIN.NS Bollinger Bands (20, 2) Analysis




LUPIN.NS - Supertrend Summary

Status: UPTREND (Buy)

Supertrend Value: 2089.93

Signal Identified On: 2025-11-12


Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




LUPIN.NS - MACD Summary

MACD Line:	8.72
Signal Line:	16.17
Histogram:	-7.45
Trend:	Bearish
Momentum:	Weakening
Signal:	None

LUPIN.NS Price




LUPIN.NS MACD (12, 26, 9)



LUPIN.NS - Volatility Squeeze Summary

BB Width:	0.0608
ATR:	45.7214
Total Signals:	32
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr)
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr)
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
Signal 5:	BB Squeeze (Bullish Breakout) at 2026-01-06 00:00:00+05

LUPIN.NS - Volatility Squeeze Analysis



LUPIN.NS - RSI-Volume Summary

Current RSI:	52.70
Current Volume:	1149131
Volume MA 20:	826387
Bullish Divergences:	0
Bearish Divergences:	3
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
Bearish Div 2:	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

LUPIN.NS RSI-Volume Divergence Analysis



LUPIN.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status: 38 Signals Detected

:

2026-01-16 [-]: Distribution Day



2026-01-19 [-]: Distribution Day

2026-01-20 [-]: Distribution Day

2026-01-21 [-]: Distribution Day

2026-01-28 [-]: Distribution Day

LUPIN.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	2025.98	2152.8	2025-12-01
1 Day	UPTREND (Buy)	2089.93	2152.8	2025-11-12
15 Min	DOWNTREND (Sell)	2157.19	2152.8	2026-01-30

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bullish	Strengthening	No Signal

LUPIN.NS - 1 Week (Candlestick + EMAs)



LUPIN.NS - 1 Day (Candlestick + EMAs)



LUPIN.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - LUPIN_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) Login / Sign up

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd. [①](#)
NSE: LUPIN | BSE: 500257
Lupin Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive [①](#) In 1 Starfolio Basket

2152.80 20.70 (0.97%) **1.2M** NSE+BSE Volume
↑ Near 52W High of ₹2226.30 NSE 30 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

[Preset Metrics](#) [Default Metrics](#)

Lupin Key Metrics

Market Capitalization > High in industry	98,376	PE TTM > Above Industry Median	22.7	PEG TTM > Below Industry Median	0.4	Price to Book > Above Industry Median	Key Metrics
Institutional holding current Qtr % > High in Industry	47.1	Revenue Growth Qtr YoY % > Below Industry Median	24.2	Operating Revenue growth TTM % > Above Industry Median	15.5	Net Profit Qtr Growth YoY % > Below Industry Median	DVM
Net Profit TTM Growth % > Above Industry Median	64.7	Operating Profit Margin Qtr % > High in industry	33.2	Operating Profit Margin TTM % > High in industry	27.3	Piotroski Score > Above Industry Median	Price Chart
Rel Perf vs Nifty50 quarter% >	12.8	Rel Perf vs Sector quarter% >	15	ROE Annual % > High in industry	19.1		Forecaster

All financials are in INR Cr and price data in INR

Durability & Valuation Scores
Free [SIGN IN](#) to see details

Momentum Score [①](#) **60.7** /100
Technically Moderately Bullish

[FORECASTER](#) Please [SUBSCRIBE](#) to view forecast

[Strong Performer, Getting Expensive](#) These stocks are strong in quality and technicals but have medium valuation. At somewhat expensive v... [View Similar](#) [Embed DVM](#)

Trendlyne Snapshot - LUPIN_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners **Subscribe** Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF Login / Sign up

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

Lupin Ltd.

NSE: LUPIN | BSE: 500257

Strong Performer, Getting Expensive In 1 Starfolio Basket

2152.80 20.70 (0.97%) Near 52W High of ₹2226.30

1.2M NSE+BSE Volume NSE 30 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes **TRADE STOCK**

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News ▾ Reports Technicals ▾ Shareholding ▾ Deals ▾ Corporate Actions ▾ Alerts About

Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2306, revenue growth forecast of 14.8%, and profit growth estimate of 37.7% for FY26, based on top 37 analyst calls.



Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

Upgrade Now**Sign in**

SAMPLE DATA BELOW

